1,3-Dimethyl-7-substituted-1,2,3,4-tetrahydroisoquinolines as probes for the binding orientation of tetrahydroisoquinoline at the active site of phenylethanolamine N-methyltransferase

Bioorganic and Medicinal Chemistry

Volumn 7, Issue 5, 1999, Pages 869-880

  Grunewald, Gary L ^a   Caldwell, Timothy M ^a   Li, Qifang ^a   Criscione, Kevin R ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Antihypertension; Enzyme inhibitors; Neurologically active cmpds; Stereospecificity

Indexed keywords

1,2,3,4 TETRAHYDRO 7 ISOQUINOLINESULFONAMIDE; 7,8 DICHLORO 1,2,3,4 TETRAHYDROISOQUINOLINE; ALPHA 2 ADRENERGIC RECEPTOR; PHENYLETHANOLAMINE N METHYLTRANSFERASE; TETRAHYDROISOQUINOLINE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN HOMOGENATE; CONTROLLED STUDY; DRUG BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; LIPOPHILICITY; MALE; NONHUMAN; RADIOASSAY; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; CATTLE; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; ISOQUINOLINES; KINETICS; MODELS, MOLECULAR; PHENYLETHANOLAMINE N-METHYLTRANSFERASE; RECEPTORS, ADRENERGIC; STEREOISOMERISM;

EID: 0033135059     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(99)00031-0     Document Type: Article

References (49)

1. This paper is dedicated to the memory of Sir D. H. R. Barton for the fundamental contributions he made in conformation and its importance in chemistry. It was Barton, at a cocktail party following a research seminar at the University of Wisconsin in the 1950s, who discussed with Edward E. Smissman the thoughts Barton had of the importance of conformation to organic chemistry that sparked Smissman's realization of the relevance of conformation to the interaction of drugs with receptors. Smissman embarked on his highly successful research in the 1950s and 1960s to exploit this with the design and synthesis of conformationally-restricted (rigid) analogues of drugs and neurotransmitters. Today the concept of rigid analogues in drug design is taken for granted, and it was Smissman, later reinforced by conversations this author had with Barton, that sparked my own interest in applications of the concept of rigid analogues to an understanding of the molecular mechanism of action of amphetamine, and further to the subject of this paper. Both men were giants in their field, and it is noteworthy that there was a synergism in the recognition of the work of one by the other in ways that neither would have seen alone.
2. Taken in large part from the Ph.D. dissertation of T.M.C., University of Kansas, 1998.
3. von Euler, U. S. A. Acta Physiol. Scand. 1946, 12, 73-97.
4. Vogt, M. J. Physiol. (Lond.) 1954, 123, 451-481.
5. Gunne, L.-M. Acta Physiol. Scand. 1962, 56, 324-333.
6. McGeer, P. L.; McGeer, E. G. Biochem. Biophys. Res. Commun. 1964, 17, 502-507.
7. Howe, P. R. C.; Costa, M.; Furness, J. B.; Chalmers, J. P. Neuroscience 1980, 5, 2229-2238.
8. Gugten, J. V. D.; Palkovits, M.; Wijnen, H. L. J. M.; Versteeg, D. H. G. Brain Res. 1976, 107, 171-175.
9. Mefford, I.; Oke, A.; Keller, R.; Adams, R. N.; Jonsson, G. Neurosci. Lett. 1978, 9, 227-231.
10. Crowley, W. R.; Terry, L. C.; Johnson, M. D. Endocrinology 1982, 110, 1102.
11. Trudeau, F.; Brisson, G. R.; Péronnet, F. Physiology & Behaviour 1992, 52, 389-392.
12. Mefford, I. N.; Lister, R. G.; Ota, M.; Linnoila, M. Alcoholism 1990, 14, 53-57.
13. Masaharu, K.; Atobe, M.; Nakagawara, M.; Kariya, T. Neuropsychobiology 1996, 33, 132-137.
14. Atobe, M.; Kubota, M.; Nakagawara, M.; Kariya, T. Neuropsychobiology 1996, 34, 82-89.
15. Burke, W. J.; Chung H. D.; Strong, R.; Mattammal, M. B.; Marshall, G. L.; Nakra, R.; Grossberg, G. T.; Haring, J. H.; Joh, T. H. 'Mechanism of Degeneration of Epinephrine Neurons in Alzheimer's Disease' pp. 41-70. in Central Nervous System Disorders of Aging: Clinical Intervention and Research, Eds. Strong R. et. al. Raven Press: New York, 1988.
16. Burke, W. J.; Galvin, N. J.; Chung, H. D.; Stoff, S. A.; Gillespie, K. N.; Cataldo, A. M.; Nixon, R. A. Brain Res. 1994, 661, 35-42.
17. Fuller, R. W.; Molloy, B. B.; Hemrick, S. K. Biochem. Pharmacol. 1979, 28, 528-530.
18. Toomey, R. E.; Horng, J. S.; Hemrick-Luecke, S. K.; Fuller, R. W. Life Sci. 1981, 29, 2467-2472.
19. Goldstein, M.; Saito, M.; Lew, J. Y.; Hieble, J. P.; Pendleton, R. G. Eur. J. Pharmacol. 1980, 67, 305-308.
20. Drew, G. M. J. Pharm. Pharmacol. 1981, 33, 187-188.
21. Pendleton, R. J.; Hieble, J. P. Res. Commun. Chem. Pathol. Pharmacol. 1981, 34, 399-408.
22. Bondinell, W. E.; Chapin, R. W.; Girard, G. R.; Kaiser, C.; Krog, A. J.; Pavloff, A. M.; Schwartz, M. S.; Silvestri, J. S.; Vaidya, P. D.; Lam, B. L.; Wellman, G. R.; Pendleton, R. G. J. Med. Chem. 1980, 23, 506-511.
23. Goldstein, M.; Kinguasa, K.; Hieble, J. P.; Pendleton, R. G. Life Sci. 1982, 30, 1951-1957.
24. Cramer, R. D., III; Patterson, D. E.; Bunce, J. D. J. Am. Chem. Soc. 1988, 110, 5959-5967.
25. Grunewald, G. L.; Dahanukar, V. H.; Jalluri, R. K.; Criscione, K. R. J. Med. Chem. 1999, 42, 118-134.
26. Pendleton, R. G.; Gessner, G.; Weiner, G.; Jenkins, B.; Sawyer, J.; Bondinell, W.; Intoccia, A. J. Pharmacol. Exp. Ther. 1979, 208, 24-30.
27. Grunewald, G. L; Sall, D. L.; Monn, J. A. J. Med. Chem. 1988, 31, 433-444.
28. Grunewald, G. L.; Sall, D. J.; Monn, J. A. J. Med. Chem. 1988, 31, 824-830.
29. Dahanukar, Vilas H., Ph.D. dissertation, University of Kansas, Lawrence, KS, 1994.
30. Bringman, G.; Weirich, R.; Reuscher, H.; Jansen, J. R.; Kinzinger, L.; Ortman, T. Liebigs Ann. Chem. 1993, 877-888.
31. Repke, D. B.; Bates, D. K.; Ferguson, W. J. J. Pharm. Sci. 1978, 67, 1167-1168.
32. 20 =+20° (c 0.79, EtOH).
33. Takahata, H.; Ishikura, M.; Yamazaki, T. Chem. Pharm. Bull. 1980, 28, 220-226.
34. Ingold, C. K.; Wilson, C. L. J. Chem. Soc. 1933, 1493-1505.
35. Wender, P. A.; Schaus, J. M. J. Org. Chem. 1978, 43, 782-784.
36. McCoubrey, A.; Mathieson, D. W. J. Chem. Soc. 1951, 2851-2853.
37. Connett, R. J.; Kirshner, N. J. Biol. Chem. 1970, 245, 329-334.
38. Grunewald, G. L.; Borchardt, R. T.; Rafferty, M. F.; Krass, P. Mol. Pharmacol. 1981, 20, 377-381.
39. U'Prichard, D. C.; Greenberg, D. A.; Snyder, S. H. Mol. Pharmacol. 1977, 13, 454-473.
40. Potapov, V. M.; Dem'yanovich, V. M.; Soifer, V. S.; Terent'ev, A. P. Zhur. Obsch. Khim. 1966, 37, 2679-2685.
41. Altomare, A.; Cascarano, M.; Giacovazzo, C.; Guagliardi, A. J. Appl. Cryst. 1993, 26, 343.
42. Beurskens, P. T.; Admiraal, G.; Beurskens, G.; Bosman, W. P.; de Gelder, R.; Israel, R.; Smits, J. M. M. The DIRDIF-94 program system, Technical Report of the Crystallography Laboratory, University of Nijmegen, The Netherlands 1994.
43. o)=e.s.d. based on counting statistics and p=p- factor.
44. v=number of variables.
45. Cromer, D. T.; Waber, J. T. 'International Tables for X-ray Crystallography', The Kynoch Press: Birmingham, England, 1974; Vol. 4, Table 2.2 A.
46. Ibers, J. A.; Hamilton, W. C. Acta Crystallogr. 1964, 17, 781.
47. Creagh, D. C.; McAuley, W. J. 'International Tables for Crystallography'; Ed., Wilson, A. J. C.; Kluwer Academic Publishers; Boston, 1992, Vol. C, pp 219-222, Table 4.2.6.8.
48. Creagh, D. C.; Hubbell, J. H. 'International Tables for Crystallography'; Ed., Wilson, A. J. C.; Kluwer Academic Publishers; Boston, 1992, Vol. C, pp 200-206, Table 4.2.4.3.
49. teXsan for Windows: Crystal Structure Analysis Package, Molecular Structure Corporation 1997.